Bruker Corporation (NASDAQ:BRKR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Brokerages give Bruker a “Moderate Buy” consensus based on 14 ratings, with six buys, two strong buys, four holds and two sells. The average 12-month price target is approximately $56.64, though several firms recently raised their targets, including Leerink Partners to $70.
• Bruker’s latest quarter exceeded earnings expectations, reporting $0.49 EPS versus the $0.38 consensus, while revenue rose 5.2% year over year to $838.5 million but fell short of estimates.
• The company declared a quarterly dividend of $0.05 per share, equivalent to a 0.3% annual yield, while institutional investors own approximately 79.5% of outstanding shares.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen ratings firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $56.6429.

BRKR has been the subject of a number of research analyst reports. Barclays boosted their target price on shares of Bruker from $53.00 to $60.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Weiss Ratings raised Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. lifted their price objective on Bruker from $55.00 to $65.00 and gave the stock an "overweight" rating in a research note on Monday, June 8th. Wolfe Research initiated coverage on Bruker in a research report on Monday, June 1st. They set a "peer perform" rating for the company. Finally, Leerink Partners increased their target price on Bruker from $60.00 to $70.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th.

Bruker Trading Up 3.1%

Shares of BRKR stock opened at $58.65 on Thursday. Bruker has a 12 month low of $28.53 and a 12 month high of $65.30. The company has a market cap of $8.94 billion, a PE ratio of -83.79, a price-to-earnings-growth ratio of 1.74 and a beta of 1.28. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The business's 50 day moving average is $58.46 and its two-hundred day moving average is $47.28.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker will post 2.12 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker's payout ratio is -28.57%.

Institutional Investors Weigh In On Bruker

Hedge funds have recently modified their holdings of the business. Orbis Allan Gray Ltd increased its position in Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock worth $702,256,000 after acquiring an additional 761,258 shares during the period. Pallas Capital Advisors LLC bought a new stake in Bruker in the 2nd quarter valued at $570,746,000. State Street Corp grew its position in Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock worth $180,700,000 after purchasing an additional 91,706 shares during the last quarter. AQR Capital Management LLC grew its position in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Finally, Sculptor Capital LP increased its holdings in shares of Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock worth $118,112,000 after purchasing an additional 270,000 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source